Rafael Holdings Inc - Ordinary Shares - Class B
RFL
Get informed when a big investor buys or sells
+ FollowMarket Cap$50.35M
Close$
$0.62
54% downside
Current Fair Value
54% downsideOvervalued by 54% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $50.35 Million |
|---|---|
| Enterprise Value | $13.23 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.04 |
| Beta | 0.5 |
| Outstanding Shares | 51,226,095 |
Return
| Return on Equity | -41.82% |
|---|---|
| Return on Assets | -33.33% |
| Return on Invested Capital | -35.47% |
Valuation & Multiples
| P/E Ratio | -2.12 |
|---|---|
| PEG | -5.54 |
| Price to Sales | - |
| Price to Book Ratio | 1.35 |
| Enterprise Value to Revenue | 11.37 |
| Enterprise Value to EBIT | -0.43 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 16, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
June 10, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 141,000▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.85%▼ 0.86% |
|---|---|
| Total Invested | $4.39M▼ 5.86% |
| Investors Holding | 42▲ 2.00% |
ESG Score
No data
About Rafael Holdings Inc
57 employeesRafael Holdings is focused on development of novel cancer therapies. The Company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. Through its wholly own...